Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial combination presented as a tablet for oral use. It prevents and treats malaria infection, including acute uncomplicated Plasmodium falciparum malaria, in travelers and residents of endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial drug used for both prophylaxis and treatment of malaria infections.

Prevention of malaria infection: provides chemoprophylaxis for travelers to endemic areas. Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears parasitemia and resolves symptoms. Chemoprophylaxis of malaria in residents of endemic regions: reduces incidence of new infections during high‑risk periods.

Malarone may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Abdominal pain - Headache - Dizziness - Loss of appetite - Vomiting

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction or elevated liver enzymes - Hemolysis in patients with G6PD deficiency - Anaphylactic or severe allergic reactions - Neutropenia or other blood dyscrasias - Thrombocytopenia

Before prescribing Malarone, clinicians should consider several safety aspects.

Assess G6PD deficiency: avoid use in patients at risk of hemolysis. Monitor liver function: periodic testing is advised during prolonged therapy. Avoid in severe renal impairment: dosage adjustment may be required. Use with caution in pregnancy and breastfeeding: safety data are limited. Review concomitant medications that may affect absorption or metabolism. Store at ambient temperature: keep in the original pack, protect from moisture.

Malarone can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Rifampin: induces metabolism and reduces drug levels. - Antacids containing aluminum or magnesium: decrease atovaquone absorption. - Cholestyramine or other bile‑acid sequestrants: markedly lower drug bioavailability.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin): may increase atovaquone concentrations. - HIV protease inhibitors (e.g., atazanavir): can raise drug levels, requiring monitoring. - Warfarin: monitor INR as anticoagulant effect may be potentiated. - Digoxin: observe for possible increased serum concentrations.